In this issue:
- Neoadjuvant chemotherapy ± camrelizumab in resectable oesophageal SCC
- Induction-concurrent chemo-RT ± sintilimab in locoregionally advanced nasopharyngeal carcinoma
- Adding tislelizumab to first-line chemotherapy in advanced gastric/gastro-oesophageal junction adenocarcinoma
- Adjuvant trastuzumab for 9 weeks vs. 1 year in HER2-positive breast cancer
- OS, treatment duration and rechallenge outcomes with ICIs for recurrent/metastatic head and neck SCC
- Outcomes after ICI discontinuation in advanced solid tumours
- Nivolumab ± ipilimumab for advanced or metastatic high-TMB solid tumours
- ICI-induced cardiotoxicity
- Major osteoporotic fractures after ICI therapy
- Safety of trastuzumab deruxtecan: focus on interstitial lung disease/pneumonitis
Please login below to download this issue (PDF)